Recovery of the ciliated epithelium following acute bronchiolitis in infancy

Wong, J. Y. W.; Rutman, A.; O'Callaghan, C.
July 2005
Thorax;Jul2005, Vol. 60 Issue 7, p582
Academic Journal
Background: Little is known about the longitudinal changes in the ciliated respiratory epithelium of infants following viral bronchiolitis. A study was undertaken to investigate the time required for the ciliated epithelium to return to normal following bronchiolitis in infants treated with inhaled steroids or placebo. Methods: Thirty one previously healthy term infants were studied as part of a clinical trial to determine the effect of 12 weeks of treatment with inhaled fluticasone (FP) or placebo via a spacer device (17 FP, 14 placebo). Nineteen healthy children aged 0-6 years previously studied in our department were used as controls. Nasal biopsy specimens were taken from infants with bronchiolitis and ciliary beat frequency (CBF) was measured before treatment and repeated 3, 6, 12, and 24 weeks later. The epithelial ultrastructure was examined by transmission electron microscopy and a normal errors mixed model based on normal controls was used to examine the time for cilia to return to normal in bronchiolitic infants. Results: The mean CBF of infants with bronchiolitis (in Hz) at weeks 0, 3, 6, 12, and 24 were 0.5 (n = 4), 10.9 (n=4), 12.0 (n=9), 11.9 (n=8), and 12.1 (n=7) in the placebogroup and 10.6 (n=6), 11.4 (n = 9), 8.8 (n = 8), 10.9 (n = 4), and 1 3.2 (n =7) in the FP group. The time for the epithelial ultrastructure to normalise was as follows: epithelial integrity score (13.1 weeks), % ciliated cells with loss of cilia (14.0 weeks), and % epithelial cells with abnormalities in protection (16.7 weeks) or mitochondria (15.9 weeks). Inhaled steroids had no significant effects on CBF or epithelial ultrastructure. Conclusion: Ciliary loss and epithelial abnormalities persist on average for 13-17 weeks following acute bronchiolitis in infancy.


Related Articles

  • Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease. Beresford, M.W.; Primhak, R.; Subhedar, N.V.; Shaw, N.J. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jul2002, Vol. 87 Issue 1, pF62 

    In a double blind randomised controlled trial, 30 infants with chronic lung disease received fluticasone propionate or placebo for one year. There were no significant differences between treatment groups in the incidence of any day or night time symptoms or any other outcome measures.

  • Efficacy of an executive function intervention programme in MS: a placebo-controlled and pseudo-randomized trial. Fink, Frauke; Rischkau, Eva; Butt, Martina; Klein, Jan; Eling, Paul; Hildebrandt, Helmut // Multiple Sclerosis (13524585);Sep2010, Vol. 16 Issue 9, p1148 

    We evaluated a rehabilitation programme for executive deficits in multiple sclerosis patients by comparing outcome scores of a cognitive intervention group (CIG; n = 11) with those of a placebo group (n = 14) and an untreated group (n = 15). Executive functioning and verbal learning improved...

  • Frequency and circumstances of placebo use in clinical practice - a systematic review of empirical studies. Fässler, Margrit; Meissner, Karin; Schneider, Antonius; Linde, Klaus // BMC Medicine;2010, Vol. 8, p15 

    Background: The use of placebo interventions outside clinical trials is ethically, professionally and legally controversial. Little is known about the frequency and circumstances of placebo use in clinical practice. Our aim was to summarize the available empirical studies addressing these...

  • Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants. Madhi, Shabir A.; Cunliffe, Nigel A.; Steele, Duncan; Witte, Desir�e; Kirsten, Mari; Louw, Cheryl; Ngwira, Bagrey; Victor, John C.; Gillard, Paul H.; Cheuvart, Brigitte B.; Han, Htay H.; Neuzil, Kathleen M. // New England Journal of Medicine;1/28/2010, Vol. 362 Issue 4, p289 

    Background: Rotavirus is the most common cause of severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African children. Methods: We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants;...

  • Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) - study protocol. Crowther, Caroline A.; Middleton, Philippa F.; Wilkinson, Dominic; Ashwood, Pat; Haslam, Ross // BMC Pregnancy & Childbirth;2013, Vol. 13 Issue 1, p1 

    Background: Magnesium sulphate is currently recommended for neuroprotection of preterm infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high quality evidence of benefit. However there remains uncertainty as to whether these benefits apply at higher...

  • Oral Lactoferrin Supplementation to Prevent Late-Onset Neonatal Sepsis. Jenson, Hal B. // Infectious Disease Alert;Nov2009, Vol. 29 Issue 2, p13 

    A PROSPECTIVE, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, randomized clinical trial was conducted of oral supplementation of bovine lactoferrin (BLF) alone or in combination with the probiotic Lactobacillus rhamnosus GG (LGG) to reduce the incidence of lateonset sepsis (> 72 hours after...

  • Effect of Multivitamin Supplementation on the Neurodevelopment of HIV-Exposed Tanzanian Infants: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Manji, Karim P.; McDonald, Christine M.; Kupka, Roland; Bosch, Ronald J.; Kisenge, Rodrick; Aboud, Said; Bellinger, David C.; Fawzi, Wafaie W.; Duggan, Christopher P. // Journal of Tropical Pediatrics;Aug2014, Vol. 60 Issue 4, p279 

    Background: Micronutrient deficiencies and in utero exposure to HIV may impair infant neurodevelopment.Objective: To evaluate the effect of daily multivitamin supplementation on the cognitive, language and motor development of HIV-exposed Tanzanian infants.Methods: A total of 2387 infants were...

  • Early treatment. Comi, G. // Neurological Sciences;May2006 Supplement 1, Vol. 27, ps8 

    Class I clinical trials demonstrated that immunomodulatory treatments (interferon-� and glatiramer acetate) reduce the disease activity and the accumulation of disability in relapsing�remitting multiple sclerosis (MS). Moreover, interferon-�-1b had similar positive effects also in...

  • Lessons learned from long-term multiple sclerosis treatment trials. Marriott, James J.; O'Connor, Paul W. // Multiple Sclerosis (13524585);Sep2010, Vol. 16 Issue 9, p1028 

    The article discusses the results of a clinical trial on the role of continuous long-term immunomodulatory therapy in relapsing multiple sclerosis (MS). A 15-year analysis of the U.S. prospective open-label study of glatiramer acetate, was made in relapsing remitting multiple sclerosis (RRMS)....


Read the Article


Sign out of this library

Other Topics